https://www.selleckchem.com/products/mli-2.html
Tedizolid was noninferior to linezolid for day 28 ACM rate 28.1% and 26.4%, respectively (difference, -1.8%; 95% confidence interval [CI] -8.2 to 4.7). Noninferiority of tedizolid was not demonstrated for investigator-assessed clinical cure at TOC (tedizolid, 56.3% vs linezolid, 63.9%; difference, -7.6%; 97.5% CI -15.7 to 0.5). In post hoc analyses, no single factor accounted for the difference in clinical response between treatment groups. Drug-related adverse events occurred in 8.1% and 11.9% of patients who received tedizolid and linez
Like
Comment
Share
